Abstract
Influenza vaccines are the mainstay of efforts to reduce the substantial health burden from seasonal influenza. Inactivated influenza vaccines have been available since the 1940s and are administered via intramuscular injection. Inactivated vaccines can be given to anyone six months of age or older. Live attenuated, cold-adapted influenza vaccines (LAIV) were developed in the 1960s but were not licensed in the United States until 2003, and are administered via nasal spray. Both vaccines are trivalent preparations grown in eggs and do not contain adjuvants. LAIV is licensed for use in the United States for healthy nonpregnant persons 2–49 years of age.
Influenza vaccination induces antibodies primarily against the major surface glycoproteins hemagglutinin (HA) and neuraminidase (NA); antibodies directed against the HA are most important for protection against illness. The immune response peaks at 2–4 weeks after one dose in primed individuals. In previously unvaccinated children <9 years of age, two doses of influenza vaccine are recommended, as some children in this age group have limited or no prior infections from circulating types and subtypes of seasonal influenza. These children require both an initial priming dose and a subsequent booster dose of vaccine to mount a protective antibody response.
The most common adverse events associated with inactivated vaccines are sore arm and redness at the injection site; systemic symptoms such as fever or malaise are less commonly reported. Guillian–Barré Syndrome (GBS) was identified among approximately 1 per 100,000 recipients of the 1976 swine influenza vaccine. The risk of influenza vaccine-associated GBS from seasonal influenza vaccine is thought to be at most approximately 1–2 cases per 1 million vaccinees, based on a few studies that have found an association; other studies have found no association.
The most common adverse events associated with LAIV are nasal congestion, headache, myalgias or fever. Studies of the safety of LAIV among young children suggest an increased risk of wheezing in some young children, and the vaccine is not recommended for children younger than 2 years old, ages 2-4 old with a history of recurrent wheezing or reactive airways disease, or older persons who have any medical condition that confers an increased risk of influenza-related complications.
The effectiveness of influenza vaccines is related predominantly to the age and immune competence of the vaccinee and the antigenic relatedness of vaccine strains to circulating strains. Vaccine effectiveness in preventing laboratory-confirmed influenza illness when the vaccine strains are well matched to circulating strains is 70–90% in randomized, placebo-controlled trials conducted among children and young healthy adults, but is lower among elderly or immunocompromised persons. In years with a suboptimal match, vaccine benefit is likely to be lower, although the vaccine can still provide substantial benefit, especially against more severe outcomes. Live, attenuated influenza vaccines have been most extensively studied among children, and have been shown to be more effective than inactivated vaccines in several randomized controlled trials among young children.
Influenza vaccination is recommended in the United States for all children six months or older, all adults 50 years or older, all persons with chronic medical conditions, and pregnant women, and contacts of these persons, including healthcare workers. The global disease burden of influenza is substantial, and the World Health Organization has indicated that member states should evaluate the cost-effectiveness of introducing influenza vaccination into national immunization programs. More research is needed to develop more effective seasonal influenza vaccines that provide long-lasting immunity and broad protection against strains that differ antigenically from vaccine viruses.
Keywords
- Influenza Virus
- Influenza Vaccine
- Influenza Vaccination
- Influenza Season
- Vaccine Adverse Event Reporting System
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Abramson JS, Neuzil KM, Tamblyn SE (2006) Annual universal influenza vaccination: ready or not? Clin Infect Dis 42:132–135
Ahmed AH et al. (1997) Effectiveness of influenza vaccine in reducing hospital admissions during the 1989–90 epidemic. Epidemiol Infect 118:27–33
Alexandrova GI et al. (1986) Study of live recombinant cold-adapted influenza bivalent vaccine of type A for use in children: an epidemiological control trial. Vaccine 4:114–118
Ali T et al. (2004) Detection of influenza antigen with rapid antibody-based tests after intranasal influenza vaccination (Flumist). Clin Infect Dis 38:760–762
Allison MA et al. (2006) Influenza vaccine effectiveness in healthy 6- to 21-month-old children during the 2003–2004 season. J Pediatr 149:755–762
Anon (1944) A clinical evaluation of vaccination against influenza. JAMA 124:982–985
Arden NH, Patriarca PA, Kendal AP (1986) Experiences in the use and efficacy of inactivated influenza vaccine in nursing homes. In: Kendal AP, Patriarca PA (eds) Options for the control of influenza. Alan R. Liss, New York, pp 155–168
Ashkenazi S et al. (2006) Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J 25:870–879
Audicana MT et al. (2002) Allergic contact dermatitis from mercury antiseptics and derivatives: study protocol of tolerance to intramuscular injections of thimerosal. Am J Contact Dermat 13:3–9
Babcock HM, Merz LR, Fraser VJ (2006) Is influenza an influenza-like illness? Clinical presentation of influenza in hospitalized patients. Infect Control Hosp Epidemiol 27:266–270
Baez M, Palese P, Kilbourne ED (1980) Gene composition of high-yielding influenza vaccine strains obtained by recombination. J Infect Dis 141:362–365
Barker WH (1986) Excess pneumonia and influenza associated hospitalization during influenza epidemics in the United States, 1970–78. Am J Public Health 76:761–765
Barry DW et al. (1976) Comparative trial of influenza vaccines. II. Adverse reactions in children and adults. Am J Epidemiol 104:47–59
Belshe RB, Gruber WC (2000) Prevention of otitis media in children with live attenuated influenza vaccine given intranasally. Pediatr Infect Dis J 19:S66–S71
Belshe RB, Mendelman PM (2003) Safety and efficacy of live attenuated, cold-adapted, influenza vaccine-trivalent. Immunol Allergy Clin North Am 23:745–767
Belshe RB et al. (1998) The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med 338:1405–1412
Belshe RB et al. (2000a) Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr 136:168–175
Belshe RB et al. (2000b) Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis 181:1133–1137
Belshe RB et al. (2004) Safety, efficacy, and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population aged 5–49 years. Clin Infect Dis 39:920–927
Belshe RB et al. (2007) Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 356:685–696
Bergen R et al. (2004) Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents. Pediatr Infect Dis J 23:138–144
Beyer WE et al. (1998) The plea against annual influenza vaccination? “The Hoskins’ Paradox” revisited. Vaccine 16:1929–1932
Bhat N et al. (2005) Influenza-associated deaths among children in the United States, 2003–2004. N Engl J Med 353:2559–2567
Block SL et al. (2008) Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age. Vaccine 26:4940–6
Bridges CB et al. (2000) Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial. JAMA 284:1655–1663
Bright RA et al. (2006) Adamantane resistance among influenza A viruses isolated early during the 2005–2006 influenza season in the United States. JAMA 295:891–894
Brokstad KA et al. (1995) Parenteral influenza vaccination induces a rapid systemic and local immune response. J Infect Dis 171:198–203
Brooks WA et al. (2007) Human metapneumovirus infection among children, Bangladesh. Emerg Infect Dis 13:1611–1613
Buonagurio DA et al. (2006) Genetic and phenotypic stability of cold-adapted influenza viruses in a trivalent vaccine administered to children in a day care setting. Virology 347:296–306
Carrat F, et al. (2008) Time lines of infection and disease in human influenza: a review of volunteer challenge studies. Am J Epidemiol 167:775–85
Carman WF et al. (2000) Effects of influenza vaccination of health-care workers on mortality of elderly people in long-term care: a randomised controlled trial. Lancet 355:93–97
Cate TR et al. (1977) Clinical trials of monovalent influenza A/New Jersey/76 virus vaccines in adults: reactogenicity, antibody response, and antibody persistence. J Infect Dis 136(Suppl):S450–S455
Cate TR et al. (1983) Reactogenicity, immunogenicity, and antibody persistence in adults given inactivated influenza virus vaccines—1978. Rev Infect Dis 5:737–747
CDC (1992) Outbreak of influenza A in a nursing home—New York, December 1991–January 1992. MMWR 41:129–131
CDC (2007) Update: influenza activity—United States and Worldwide, May 20–September 17, 2007. MMWR 56:1001–1004
Cha TA et al. (2000) Genotypic stability of cold-adapted influenza virus vaccine in an efficacy clinical trial. J Clin Microbiol 38:839–845
Chen Z et al. (2006) Genetic mapping of the cold-adapted phenotype of B/Ann Arbor/1/66, the master donor virus for live attenuated influenza vaccines (flumist). Virology 345:416–423
Choi K, Thacker SB (1982) Mortality during influenza epidemics in the United States, 1967–1978. Am J Public Health 72:1280–1283
Clover RD et al. (1991) Comparison of heterotypic protection against influenza A/Taiwan/86 (H1N1) by attenuated and inactivated vaccines to A/Chile/83-like viruses. J Infect Dis 163:300–304
Coles FB, Balzano GJ, Morse DL (1992) An outbreak of influenza A (H3N2) in a well immunized nursing home population. J Am Geriatr Soc 40:589–592
Colombo C et al. (2001) Influenza vaccine in healthy preschool children. Rev Epidemiol Sante Publique 49:157–162
Connolly AM et al. (1993) What are the complications of influenza and can they be prevented? Experience from the 1989 epidemic of H3N2 influenza A in general practice. BMJ 306:1452–1454
Corey L et al. (1976) A nationwide outbreak of Reye’s syndrome. Its epidemiologic relationship to influenza B. Am J Med 61:615–625
Cox NJ, Bridges CB (2007) Inactivated and live attenuated influenza vaccines in young children—how do they compare? N Engl J Med 356:729–731
Cox NJ et al. (1985) Comparative studies of A/Leningrad/134/57 wild-type and 47-times passaged cold-adapted mutant influenza viruses: oligonucleotide mapping and RNA-RNA hybridization studies. J Gen Virol 66(Pt 8):1697–1704
Creighton C (1891) A History of epidemics in Britain, AD 664–1666. Cambridge University Press, New York
Cunney RJ et al. (2000) An outbreak of influenza A in a neonatal intensive care unit. Infect Control Hosp Epidemiol 21:449–454
Davenport FM (1962) Current knowledge of influenza vaccine. JAMA 182:121–123
Davies JR, Grilli EA (1989) Natural or vaccine-induced antibody as a predictor of immunity in the face of natural challenge with influenza viruses. Epidemiol Infect 102:325–333
Deguchi Y, Takasugi Y, Tatara K (2000) Efficacy of influenza vaccine in the elderly in welfare nursing homes: reduction in risks of mortality and morbidity during an influenza A (H3N2) epidemic. J Med Microbiol 49:553–556
Demicheli V et al. (2000) Prevention and early treatment of influenza in healthy adults. Vaccine 18:957–1030
Demicheli V et al. (2004) Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev CD001269
Dharan NJ et al. (2009) Infections with oseltamivir-resistant influenza A(H1N1) viruses in the United States. JAMA 301:1034–41
Dietzman DE et al. (1976) Acute myositis associated with influenza B infection. Pediatrics 57:255–258
Doherty PC et al. (2006) Influenza and the challenge for immunology. Nat Immunol 7:449–455
Donabedian AM et al. (1988) A mutation in the PA protein gene of cold-adapted B/Ann Arbor/1/66 influenza virus associated with reversion of temperature sensitivity and attenuated virulence. Virology 163:444–451
Dowdle WR (1981) Influenza immunoprophylaxis after 30 years’ experience. In: Genetic variation among influenza viruses. Academic, New York, pp 525–534
Dowdle WR et al. (1973) Inactivated influenza vaccines. 2. Laboratory indices of protection. Postgrad Med J 49:159–163
Edwards KM, Griffin MR (2006) Influenza vaccination of children: can it be accomplished? J Infect Dis 194:1027–1029
Edwards KM et al. (1994) A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J Infect Dis 169:68–76
el-Madhun AS et al. (1998) Systemic and mucosal immune responses in young children and adults after parenteral influenza vaccination. J Infect Dis 178:933–939
Elder AG et al. (1996) Incidence and recall of influenza in a cohort of Glasgow healthcare workers during the 1993–94 epidemic: results of serum testing and questionnaire. BMJ 313:1241–1242
Englund JA et al. (2005) A comparison of 2 influenza vaccine schedules in 6- to 23-month-old children. Pediatrics 115:1039–1047
Ennis FA et al. (1977) Correlation of laboratory studies with clinical responses to A/New Jersey influenza vaccines. J Infect Dis 136(Suppl):S397–S406
Esposito S et al. (2003) Effectiveness of influenza vaccination of children with recurrent respiratory tract infections in reducing respiratory-related morbidity within the households. Vaccine 21:3162–3168
Fedson DS et al. (1993) Clinical effectiveness of influenza vaccination in Manitoba. JAMA 270:1956–1961
Fine AD et al. (2001) Influenza A among patients with human immunodeficiency virus: an outbreak of infection at a residential facility in New York City. Clin Infect Dis 32:1784–1791
Fiore AE et al. (2008) Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep 57:1–60
Fleming DM et al. (1995) Study of the effectiveness of influenza vaccination in the elderly in the epidemic of 1989–90 using a general practice database. Epidemiol Infect 115:581–589
Fleming DM et al. (2006) Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J 25:860–869
Foster DA et al. (1992) Influenza vaccine effectiveness in preventing hospitalization for pneumonia in the elderly. Am J Epidemiol 136:296–307
Fox JP et al. (1982a) Influenzavirus infections in Seattle families, 1975–1979. I. Study design, methods and the occurrence of infections by time and age. Am J Epidemiol 116:212–227
Fox JP et al. (1982b) Influenzavirus infections in Seattle families, 1975–1979. II. Pattern of infection in invaded households and relation of age and prior antibody to occurrence of infection and related illness. Am J Epidemiol 116:228–242
Francis T (1945) The development of the 1943 vaccination study of the Commission on Influenza. Am J Hyg 42:1–11
Francis T, Salk JE, Brace WM (1946) The protective effect of vaccination against epidemic influenza B. JAMA 131:275–278
Freeman DW, Barno A (1959) Deaths from Asian influenza associated with pregnancy. Am J Obstet Gynecol 78:1172–1175
Frey S et al. (2003) Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and a non-adjuvanted influenza vaccine in non-elderly adults. Vaccine 21:4234–4237
Fukuda K, Kieny MP (2006) Different approaches to influenza vaccination. N Engl J Med 355:2586–2587
Fukuda K, Thompson WW, Cox NJ (2001) To the editor: (vaccinating Japanese schoolchildren against influenza). N Engl J Med 344:1946–1947
Gaglani MJ et al. (2004) Direct and total effectiveness of the intranasal, live-attenuated, trivalent cold-adapted influenza virus vaccine against the 2000–2001 influenza A(H1N1) and B epidemic in healthy children. Arch Pediatr Adolesc Med 158:65–73
Gerhard W (2001) The role of the antibody response in influenza virus infection. Curr Top Microbiol Immunol 260:171–190
Ghendon YZ et al. (1984) Recombinant cold-adapted attenuated influenza A vaccines for use in children: molecular genetic analysis of the cold-adapted donor and recombinants. Infect Immun 44:730–733
Ghendon YZ, Kaira AN, Elshina GA (2006) The effect of mass influenza immunization in children on the morbidity of the unvaccinated elderly. Epidemiol Infect 134:71–78
Glaser CA et al. (2002) Medical care capacity for influenza outbreaks, Los Angeles. Emerg Infect Dis 8:569–574
Glezen WP (2006) Herd protection against influenza. J Clin Virol 37:237–243
Glezen WP, Couch RB (1978) Interpandemic influenza in the Houston area, 1974–76. N Engl J Med 298:587–592
Govaert TM et al. (1994) The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA 272:1661–1665
Green DM (2002) Advances in the management of guillain-barre syndrome. Curr Neurol Neurosci Rep 2:541–548
Gregg MB (1980) The epidemiology of influenza in humans. Ann N Y Acad Sci 353:45–53
Gross PA et al. (1995) The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann Intern Med 123:518–527
Gross PA et al. (1997) Time to earliest peak serum antibody response to influenza vaccine in the elderly. Clin Diagn Lab Immunol 4:491–492
Gruber WC et al. (1996) Evaluation of live attenuated influenza vaccines in children 6–18 months of age: safety, immunogenicity, and efficacy. National Institute of Allergy and Infectious Diseases, Vaccine and Treatment Evaluation Program and the Wyeth-Ayerst ca Influenza Vaccine Investigators Group. J Infect Dis 173:1313–1319
Gubareva LV et al. (1998) Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Dis 178:1257–1262
Gubareva LV et al. (2001) Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J Infect Dis 183:523–531
Hak E et al. (2002a) Influence of high-risk medical conditions on the effectiveness of influenza vaccination among elderly members of 3 large managed-care organizations. Clin Infect Dis 35:370–377
Hak E et al. (2002b) Confounding by indication in non-experimental evaluation of vaccine effectiveness: the example of prevention of influenza complications. J Epidemiol Commun Health 56:951–955
Hak E et al. (2005) Clinical effectiveness of influenza vaccination in persons younger than 65 years with high-risk medical conditions: the PRISMA study. Arch Intern Med 165:274–280
Hall CE, Cooney MK, Fox JP (1973) The Seattle virus watch. IV. Comparative epidemiologic observations of infections with influenza A and B viruses, 1965–1969, in families with young children. Am J Epidemiol 98:365–380
Halloran ME, Longini IM, Jr. (2006) Public health. Community studies for vaccinating schoolchildren against influenza. Science 311:615–616
Halperin SA et al. (2002) Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children. Vaccine 20:1240–1247
Harper SA et al. (2009) Seasonal influenza in adults and children--diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical guidelines of the Infectious Diseases Society of America 48:1003–32
Harris JW (1919) Influenza occurring in pregnant women: a statistical study of thirteen hundred and fifty cases. JAMA 72:978–980
Hauge SH et al. (2009) Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08. Emerg Infect Dis 15:155–62
Hayward AC et al. (2006) Effectiveness of an influenza vaccine programme for care home staff to prevent death, morbidity, and health service use among residents: cluster randomised controlled trial. BMJ 333:1241
Heikkinen T, Thint M, Chonmaitree T (1999) Prevalence of various respiratory viruses in the middle ear during acute otitis media. N Engl J Med 340:260–264
Heinonen OP et al. (1973) Immunization during pregnancy against poliomyelitis and influenza in relation to childhood malignancy. Int J Epidemiol 2:229–235
Helms CM et al. (2005) Strengthening the nation’s influenza vaccination system: a National Vaccine Advisory Committee assessment. Am J Prev Med 29:221–226
Herrera GA et al. (2007) Influenza vaccine effectiveness among 50–64-year-old persons during a season of poor antigenic match between vaccine and circulating influenza virus strains: Colorado, United States, 2003–2004. Vaccine 25:154–160
Hoberman A et al. (2003) Effectiveness of inactivated influenza vaccine in preventing acute otitis media in young children: a randomized controlled trial. JAMA 290:1608–1616
Hobson D et al. (1972) The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond.) 70:767–777
Hoelscher MA et al. (2006) Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet 367:475–481
Hoskins TW et al. (1973) Controlled trial of inactivated influenza vaccine containing the a-Hong Kong strain during an outbreak of influenza due to the a-England-42–72 strain. Lancet 2:116–120
Hoskins TW et al. (1979) Assessment of inactivated influenza-A vaccine after three outbreaks of influenza A at Christ’s Hospital. Lancet 1:33–35
Hurwitz ES et al. (1981) Guillain–Barre syndrome and the 1978–1979 influenza vaccine. N Engl J Med 304:1557–1561
Hurwitz ES et al. (2000a) Effectiveness of influenza vaccination of day care children in reducing influenza-related morbidity among household contacts. JAMA 284:1677–1682
Hurwitz ES et al. (2000b) Studies of the 1996–1997 inactivated influenza vaccine among children attending day care: immunologic response, protection against infection, and clinical effectiveness. J Infect Dis 182:1218–1221
Inouye S, Kramer MH (2001) To the editor: (vaccinating Japanese schoolchildren against influenza). N Engl J Med 344:1946
Irving WL et al. (2000) Influenza virus infection in the second and third trimesters of pregnancy: a clinical and seroepidemiological study. BJOG 107:1282–1289
Izurieta HS et al. (2005) Adverse events reported following live, cold-adapted, intranasal influenza vaccine. JAMA 294:2720–2725
Jackson LA et al. (1999) Safety of a trivalent live attenuated intranasal influenza vaccine, flumist, administered in addition to parenteral trivalent inactivated influenza vaccine to seniors with chronic medical conditions. Vaccine 17:1905–1909
Jackson LA et al. (2006) Evidence of bias in estimates of influenza vaccine effectiveness in seniors. Int J Epidemiol 35:337–344
Jefferson TO et al. (2007) Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev CD001269
Johnson PR, Jr. et al. (1985) Comparison of long-term systemic and secretory antibody responses in children given live, attenuated, or inactivated influenza A vaccine. J Med Virol 17:325–335
Johnson PR et al. (1986) Immunity to influenza A virus infection in young children: a comparison of natural infection, live cold-adapted vaccine, and inactivated vaccine. J Infect Dis 154:121–127
Jordan R et al. (2006) Universal vaccination of children against influenza: are there indirect benefits to the community? A systematic review of the evidence. Vaccine 24:1047–1062
Juurlink DN et al. (2006) Guillain–Barre syndrome after influenza vaccination in adults: a population-based study. Arch Intern Med 166:2217–2221
Kaplan JE et al. (1982) Guillain–Barre syndrome in the United States, 1979–1980 and 1980–1981. Lack of an association with influenza vaccination. JAMA 248:698–700
Keitel WA et al. (1997) Efficacy of repeated annual immunization with inactivated influenza virus vaccines over a five year period. Vaccine 15:1114–1122
Keitel WA et al. (2006) Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Intern Med 166:1121–1127
Keren R et al. (2005) Neurological and neuromuscular disease as a risk factor for respiratory failure in children hospitalized with influenza infection. JAMA 294:2188–2194
Kilbourne ED, Murphy JS (1960) Genetic studies of influenza viruses. I. Viral morphology and growth capacity as exchangeable genetic traits. Rapid in-ovo adaptation of early passage Asian strain isolates by combination with PRS. J Exp Med 111:387–406
Kilbourne ED et al. (1968) Antiviral activity of antiserum specific for an influenza virus neuraminidase. J Virol 2:281–288
Kim HW et al. (1979) Influenza A and B virus infection in infants and young children during the years 1957–1976. Am J Epidemiol 109:464–479
King JC et al. (2000) Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults. J Infect Dis 181:725–728
King JC, Jr. et al. (2001) Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children. Pediatr Infect Dis J 20:1124–1131
King JC, Jr. et al. (2006) Effectiveness of school-based influenza vaccination. N Engl J Med 355:2523–2532
Kiso M et al. (2004) Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364:759–765
Kistner O et al. (1999) A novel mammalian cell (Vero) derived influenza virus vaccine: development, characterization and industrial scale production. Wien Klin Wochenschr 111:207–214
Kramarz P et al. (2009) Use of oseltamivir in 12 European countires between 2002 and 2007–lack of association with the appearance of oseltamivir-resistant influenza A(H1N1) viruses
Kwong JC et al. (2006) The effect of universal influenza immunization on vaccination rates in Ontario. Health Rep 17:31–40
Kwong JC, Rosella LC, Johansen H (2007) Trends in influenza vaccination in Canada, 1996/1997 to 2005. Health Rep 18:9–19
Kwong JC et al. (2008) The effect of universal influenza immunization on mortality and health care use. PLoS Med 5:e211
LaMontagne Jr et al. (1983) Summary of clinical trials of inactivated influenza vaccine – 1978. Rev Infect Dis 5:723–736
Lasky T et al. (1998) The Guillain Barre syndrome and the 1992–1993 and 1993–1994 influenza vaccines. N Engl J Med 339:1797–1802
Lester RT et al. (2003) Use of, effectiveness of, and attitudes regarding influenza vaccine among house staff. Infect Control Hosp Epidemiol 24:839–844
LoGrippo GA (1960) Investigations of the use of beta propiolactone in virus inactivation. Ann NY Acad Sci 83:578–594
Lui KJ, Kendal AP (1987) Impact of influenza epidemics on mortality in the United States from October 1972 to May 1985. Am J Public Health 77:712–716
Maassab HF (1967) Adaptation and growth characteristics of influenza virus at 25°C. Nature 213:612–614
Maassab HF (1969) Biologic and immunologic characteristics of cold-adapted influenza virus. J Immunol 102:728–732
Maassab HF et al. (1982) Evaluation of a cold-recombinant influenza virus vaccine in ferrets. J Infect Dis 146:780–790
Mair M et al. (2006) Universal influenza vaccination: the time to act is now. Biosecur Bioterror 4:20–40
Mak TK et al. (2008) Influenza vaccination in pregnancy: current evidence and selected national policies. Lancet Infect Dis 8:44–52
MedImmune (2008) Flumist (package insert). MedImmune, Gaithersburg (see http://www.medimmune.com/pdf/products/flumist_pi.pdf)
Meijer A. et al. (2009) Oseltamivir-resistant influenza virus, Europe, 2007-08 season. Emerg Infect Dis Available from http://www.cdc.gov/EID/content/15/4/552.htm
Meiklejohn G, Hall H (1987) Unusual outbreak of influenza A in a Wyoming nursing home. J Am Geriatr Soc 35:742–746
Monto AS et al. (1970) Modification of an outbreak of influenza in Tecumseh, Michigan by vaccination of schoolchildren. J Infect Dis 122:16–25
Monto AS et al. (2000) Clinical signs and symptoms predicting influenza infection. Arch Intern Med 160:3243–3247
Monto AS, Kioumehr F (1975) The Tecumseh study of respiratory illness. IX. Occurrence of influenza in the community, 1966–1971. Am J Epidemiol 102:553–563
Monto AS, Hornbuckle K, Ohmit SE (2001) Influenza vaccine effectiveness among elderly nursing home residents: a cohort study. Am J Epidemiol 154:155–160
Morens DM, Rash VM (1995) Lessons from a nursing home outbreak of influenza A. Infect Control Hosp Epidemiol 16:275–280
Moritz A et al. (1980) Studies with a cold-recombinant A/Victoria/3/75 (H3N2) virus. II. Evaluation in adult volunteers. J Infect Dis 142:857–860
Morris JA et al. (1966) Immunity to influenza to antibody levels. N Engl J Med 274:527–535
Mullooly JP et al. (1994) Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization. Ann Intern Med 121:947–952
Neuzil KM et al. (1998) Impact of influenza on acute cardiopulmonary hospitalizations in pregnant women. Am J Epidemiol 148:1094–1102
Neuzil KM et al. (2001) Efficacy of inactivated and cold-adapted vaccines against influenza A infection, 1985 to 1990: the pediatric experience. Pediatr Infect Dis J 20:733–740
Neuzil KM, Hohlbein C, Zhu Y (2002) Illness among schoolchildren during influenza season: effect on school absenteeism, parental absenteeism from work, and secondary illness in families. Arch Pediatr Adolesc Med 156:986–991
Neuzil KM et al. (2003) Recognizing influenza in older patients with chronic obstructive pulmonary disease who have received influenza vaccine. Clin Infect Dis 36:169–174
Neuzil KM, Jackson LA, Nelson J (2006) Immunogenicity and reactogenicity of one versus two doses of trivalent inactivated influenza vaccine in vaccine-naive 5–8-year-old children. J Infect Dis
Nichol KL et al. (1995) The effectiveness of vaccination against influenza in healthy, working adults. N Engl J Med 333:889–893
Nichol KL, Wuorenma J, von Sternberg T (1998) Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. Arch Intern Med 158:1769–1776
Nichol KL et al. (1999) Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA 282:137–144
Nichol KL et al. (2007) Effectiveness of influenza vaccine in the community-dwelling elderly. N Engl J Med 357:1373–1381
Ohmit SE, Monto AS (1995) Influenza vaccine effectiveness in preventing hospitalization among the elderly during influenza type A and type B seasons. Int J Epidemiol 24:1240–1248
Ohmit SE, Arden NH, Monto AS (1999) Effectiveness of inactivated influenza vaccine among nursing home residents during an influenza type A (H3N2) epidemic. J Am Geriatr Soc 47:165–171
Ohmit SE et al. (2006) Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N Engl J Med 355:2513–2522
Ohmit SE et al. (2008) Prevention of symptomatic seasonal influenza in 2005-06 by inactivated and live attenuated vaccines. J Infect Dis 198:312–7
Orenstein WA, Bernier RH, Hinman AR (1988) Assessing vaccine efficacy in the field. Further observations. Epidemiol Rev 10:212–241
Orenstein WA et al. (2007) Financing immunization of adults in the United States. Clin Pharmacol Ther 82:764–768
Oshitani H et al. (2000) Influenza vaccination levels and influenza-like illness in long-term-care facilities for elderly people in Niigata, Japan, during an influenza A (H3N2) epidemic. Infect Control Hosp Epidemiol 21:728–730
Oya A, Nerome K (1986) Experiences with mass vaccination of young age groups with inactivated vaccines. In: Kendal AP, Patriarca PA (eds) Options for the control of influenza. Alan R. Liss, New York, pp. 183–192
Palache AM, Brands R, van Scharrenburg GJ (1997) Immunogenicity and reactogenicity of influenza subunit vaccines produced in MDCK cells or fertilized chicken eggs. J Infect Dis 176(Suppl 1):S20–S23
Palache AM et al. (1999) Safety, reactogenicity and immunogenicity of Madin Darby canine kidney cell-derived inactivated influenza subunit vaccine. A meta-analysis of clinical studies. Dev Biol Stand 98:115–125
Patriarca PA et al. (1985) Efficacy of influenza vaccine in nursing homes reduction in illness and complications during an Influenza A (H3N2) epidemic. JAMA 253:1136–1139
Percheson PB et al. (1999) A Phase I, randomized controlled clinical trial to study the reactogenicity and immunogenicity of a new split influenza vaccine derived from a non-tumorigenic cell line. Dev Biol Stand 98:127–132
Perrotta DM, Decker M, Glezen WP (1985) Acute respiratory disease hospitalizations as a measure of impact of epidemic influenza. Am J Epidemiol 122:468–476
Piedra PA et al. (2005a) Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children. Vaccine 23:1540–1548
Piedra PA et al. (2005b) Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial. Pediatrics 116:e397–e407
Piedra PA et al. (2007) Trivalent live attenuated intranasal influenza vaccine administered during the 2003–2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children. Pediatrics 120:e553–e564
Poehling KA et al. (2006) The underrecognized burden of influenza in young children. N Engl J Med 355:31–40
Potter J et al. (1997) Influenza vaccination of health care workers in long-term-care hospitals reduces the mortality of elderly patients. J Infect Dis 175:1–6
Prevots DR, Sutter RW (1997) Assessment of Guillain–Barre syndrome mortality and morbidity in the United States: implications for acute flaccid paralysis surveillance. J Infect Dis 175:S151–S155
Puig-Barbera J et al. (1997) Reduction in hospital admissions for pneumonia in non-institutionalised elderly people as a result of influenza vaccination: a case–control study in Spain. J Epidemiol Community Health 51:526–530
Quinnan GV et al. (1983) Serologic responses and systemic reactions in adults after vaccination with monovalent A/USSR/77 and trivalent A/USSR/77, A/Texas/77, B/Hong Kong/72 influenza vaccines. Rev Infect Dis 5:748–757
Reichert TA et al. (2001a) To the editor: (vaccinating Japanese schoolchildren against influenza). N Engl J Med 344:1947–1948
Reichert TA et al. (2001b) The Japanese experience with vaccinating schoolchildren against influenza. N Engl J Med 344:889–896
Ritzwoller DP et al. (2005) Effectiveness of the 2003–2004 influenza vaccine among children 6 months to 8 years of age, with 1 vs 2 doses. Pediatrics 116:153–159
Rivetti D et al. (2006) Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev 3:CD004876
Rocha E et al. (1991) Antigenic and genetic variation in influenza A (H1N1) virus isolates recovered from a persistently infected immunodeficient child. J Virol 65:2340–2350
Ropper AH (1992) The Guillain–Barre syndrome. N Engl J Med 326:1130–1136
Rudenko LG et al. (1993) Efficacy of live attenuated and inactivated influenza vaccines in schoolchildren and their unvaccinated contacts in Novgorod, Russia. J Infect Dis 168:881–887
Russell KL et al. (2005) Effectiveness of the 2003–2004 influenza vaccine among US military basic trainees: a year of suboptimal match between vaccine and circulating strain. Vaccine 23:1981–1985
Ruuskanen O et al. (1989) Acute otitis media and respiratory virus infections. Pediatr Infect Dis J 8:94–99
Saito R et al. (2002) The effectiveness of influenza vaccine against influenza a (H3N2) virus infections in nursing homes in Niigata, Japan, during the 1998–1999 and 1999–2000 seasons. Infect Control Hosp Epidemiol 23:82–86
Salgado CD et al. (2004) Preventing nosocomial influenza by improving the vaccine acceptance rate of clinicians. Infect Control Hosp Epidemiol 25:923–928
Salk JE, Menke WJ, Francis T (1945) A clinical, epidemiological and immunological evaluation of vaccination against epidemic influenza. Am J Hyg 42:57–93
Sato M et al. (2005) Antibody response to influenza vaccination in nursing home residents and healthcare workers during four successive seasons in Niigata, Japan. Infect Control Hosp Epidemiol 26:859–866
Saxen H, Virtanen M (1999) Randomized, placebo-controlled double blind study on the efficacy of influenza immunization on absenteeism of health care workers. Pediatr Infect Dis J 18:779–783
Schanzer DL, Langley JM, Tam TW (2007) Influenza-attributed hospitalization rates among pregnant women in Canada 1994–2000. J Obstet Gynaecol Can 29:622–629
Schoenbaum SC, Weinstein L (1979) Respiratory infection in pregnancy. Clin Obstet Gynecol 22:293–300
Schonberger LB et al. (1979) Guillain–Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976–1977. Am J Epidemiol 110:105–123
Schwartz B et al. (2006) Universal influenza vaccination in the United States: are we ready? Report of a meeting. J Infect Dis 194(Suppl 2):S147–S154
Shek LP, Lee BW (2003) Epidemiology and seasonality of respiratory tract virus infections in the tropics. Paediatr Respir Rev 4:105–111
Shope RE (1931) Swine influenza. I. Experimental transmission and pathology. J Exp Med 54:349–359
Shuler CM et al. (2007) Vaccine effectiveness against medically attended, laboratory-confirmed influenza among children aged 6 to 59 months, 2003–2004. Pediatrics 119:e587–e595
Simon NM, Rovner RN, Berlin BS (1970) Acute myoglobinuria associated with type A2 (Hong Kong) influenza. JAMA 212:1704–1705
Simonsen L et al. (1997) The impact of influenza epidemics on mortality: introducing a severity index. Am J Public Health 87:1944–1950
Simonsen L et al. (2000) The impact of influenza epidemics on hospitalizations. J Infect Dis 181:831–837
Simonsen L, Viboud C, Taylor RJ (2007) Effectiveness of influenza vaccination. N Engl J Med 357:2729–2730
Smith W, Andrewes CH, Laidlaw PP (1933) A virus obtained from influenza patients. Lancet 2:66–68
Smith NM et al. (2006a) Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 55:1–42
Smith S et al. (2006b) Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev CD004879
Smits AJ et al. (2002) Clinical effectiveness of conventional influenza vaccination in asthmatic children. Epidemiol Infect 128:205–211
Snyder MH et al. (1988) Four viral genes independently contribute to attenuation of live influenza A/Ann Arbor/6/60 (H2N2) cold-adapted reassortant virus vaccines. J Virol 62:488–495
Staynor K et al. (1994) Influenza A outbreak in a nursing home: the value of early diagnosis and the use of amantadine hydrochloride. Can J Infect Control 9:109–111
Stokes J et al. (1937) Results of immunization by means of active virus of human influenza. J Clin Invest 16:237–243
Strickler JK et al. (2007) Influenza vaccine effectiveness among US military basic trainees, 2005–06 season. Emerg Infect Dis 13:617–619
Sugaya N et al. (1994) Efficacy of inactivated vaccine in preventing antigenically drifted influenza type A and well-matched type B. JAMA 272:1122–1126
Surtees R, DeSousa C (2006) Influenza virus associated encephalopathy. Arch Dis Child 91:455–456
Szilagyi P et al. (2008) Influenza vaccine effectiveness among children 6 to 59 months of age during two influenza seasons: a case-cohort study. Arch Med (in press)
Talbot TR et al. (2005) Duration of virus shedding after trivalent intranasal live attenuated influenza vaccination in adults. Infect Control Hosp Epidemiol 26:494–500
Tam JS et al. (2007) Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in Asia. Pediatr Infect Dis J 26:619–628
Tasker SA et al. (1999) Efficacy of influenza vaccination in HIV-infected persons. A randomized, double-blind, placebo-controlled trial. Ann. Intern Med 131:430–433
Thomas RE et al. (2006) Influenza vaccination for health-care workers who work with elderly people in institutions: a systematic review. Lancet Infect Dis 6:273–279
Thompson T (1852) Annals of influenza or epidemic catarrhal fever in Great Britain from 1510 to 1837. Sydenham Society, London
Thompson WW et al. (2003) Mortality associated with influenza and RSV. JAMA 289:179–186
Thompson WW et al. (2004) Influenza-associated hospitalizations in the United States. JAMA 292:1333–1340
Togashi T, Matsuzono Y, Narita M (2000) Epidemiology of influenza-associated encephalitis-encephalopathy in Hokkaido, the northernmost island of Japan. Pediatr Int 42:192–196
Treanor JD (2007) Influenza—the goal of control. N Engl J Med 357:1439–1441
Treanor JJ et al. (1999) Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine 18:899–906
Vesikari T et al. (2006a) Safety, efficacy, and effectiveness of cold-adapted influenza vaccine-trivalent against community-acquired, culture-confirmed influenza in young children attending day care. Pediatrics 118:2298–2312
Vesikari T et al. (2006b) A randomized, double-blind study of the safety, transmissibility and phenotypic and genotypic stability of cold-adapted influenza virus vaccine. Pediatr Infect Dis J 25:590–595
Vu T et al. (2002) A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community. Vaccine 20:1831–1836
Wang Z, et al. (2009) Live attenuated or inactivated influenza vaccines and medical encounters for respiratory illnesses among US military personnel. JAMA 301:1066–9
Weingarten S et al. (1988) Do hospital employees benefit from the influenza vaccine? A placebo-controlled clinical trial. J Gen Intern Med 3:32–37
Weycker D et al. (2005) Population-wide benefits of routine vaccination of children against influenza. Vaccine 23:1284–1293
WHO (2005) H5N1 avian influenza: first steps towards development of a human vaccine. Wkly Epidemiol Rec 80:277–278
WHO (2008) Meeting of the immunization strategic advisory group of experts, November 2007—conclusions and recommendations. Wkly Epidemiol Rec 83:1–16
Widelock D, Csizmas L, Klein S (1963) Influenza, pregnancy, and fetal outcome. Public Health Rep 78:1–11
Wilde JA et al. (1999) Effectiveness of influenza vaccine in health care professionals: a randomized trial. JAMA 281:908–913
Williams MS, Wood JM (1993) A brief history of inactivated influenza virus vaccines. In: Hannoun C et al (eds) Elsevier, Amsterdam, pp 169–171
Willison HJ, Yuki N (2002) Peripheral neuropathies and anti-glycolipid antibodies. Brain 125:2591–2625
Wright PF et al. (1977) Trials of influenza A/New Jersey/76 virus vaccine in normal children: an overview of age-related antigenicity and reactogenicity. J Infect Dis 136(Suppl):S731–S741
Wright PF et al. (1982) Cold-adapted recombinant influenza A virus vaccines in seronegative young children. J Infect Dis 146:71–79
Wright PF et al. (1983) Antigenicity and reactogenicity of influenza A/USSR/77 virus vaccine in children—a multicentered evaluation of dosage and safety. Rev Infect Dis 5:758–764
Yamazaki T, Suzuki T, Yamamoto K (2001) To the editor: (vaccinating Japanese schoolchildren against influenza). N Engl J Med 344:1947
Yang L et al. (2008) Synchrony of clinical and laboratory surveillance for influenza in Hong Kong. PLoS ONE 3:e1399
Zaman K, et al. (2008) Effectiveness of maternal influenza immunization in mothers and infants. N Engl J Med 359:1555–64
Zangwill KM et al. (2001) Prospective, randomized, placebo-controlled evaluation of the safety and immunogenicity of three lots of intranasal trivalent influenza vaccine among young children. Pediatr Infect Dis J 20:740–746
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Fiore, A.E., Bridges, C.B., Cox, N.J. (2009). Seasonal Influenza Vaccines. In: Compans, R., Orenstein, W. (eds) Vaccines for Pandemic Influenza. Current Topics in Microbiology and Immunology, vol 333. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-92165-3_3
Download citation
DOI: https://doi.org/10.1007/978-3-540-92165-3_3
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-92164-6
Online ISBN: 978-3-540-92165-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)